Page 27 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

FDA Okays Cancer Drugs Faster Than EMA. But at What Cost?

The FDA approves new cancer drugs much sooner than its European counterpart, but is faster better? Experts discuss the pros and cons of this speedy review process. ....

United States , Stanford University , United Kingdom , Kristina Jenei , Public Health , European Medicines Agency , University Of British Columbia School Population , Stanford University School Of Medicine , Drug Administration , Friends Of Cancer Research , Department Of Oncology , Raza Khaki , Stanford University School , Medscape Medical , Allen Phd , Cancer Research , British Columbia School , Us Food And Drug Administration , Nited States Food And Drug Administration , Drug Development , Drug Discovery , Drug Pipeline , Drug Development Pipeline , Antineoplastic Drug , Nti Cancer Agents , Alignant Neoplasia ,

Blood Cell Biomarker May Predict Anthracycline LV Dysfunction

Monitoring of neutrophil-to-lymphocyte ratio could potentially help risk-stratify women on anthracycline chemotherapy for associated left-ventricular dysfunction, a prospective study suggests. ....

Tel Aviv Sourasky Medical Center , Pfizer Pharmaceuticals Israel , Israel Cardio Oncology Registry , Israel Cardio Oncology , Heart Failure , Breast Cancer , Alignant Breast Neoplasm , Alignant Neoplasia , Left Ventricular Dysfunction , Antineoplastic Drug , Nti Cancer Agents , Cardiovascular Imaging , Ardiac Imaging , V Imaging ,

Venetoclax Combos Improve Progression-Free Survival in CLL

Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern. ....

Barbara Eichhorst , University Of Cologne , European Hematology Association , Elect Ant , Medscape Medical , Chronic Lymphocytic Leukemia , Antineoplastic Drug , Nti Cancer Agents , Alignant Neoplasia , Biologic Therapy , Precision Medicine , Targeted Therapy ,

Beta Blockers May Avert Cancer-Drug Cardiotoxicity

Treatment with some beta blockers may protect cardiac contractile function during anthracycline or trastuzumab therapy, suggests a meta-analysis that also confirmed such protection by dexrazoxane. ....

Cochrane Library , Heart Failure , Antineoplastic Drug , Nti Cancer Agents , Beta Adrenergic Blockers , Alignant Neoplasia , Meta Analysis , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Cardiovascular Imaging , Ardiac Imaging , V Imaging ,

Inebilizumab Beneficial Across Genotypes in NMOSD

Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests. ....

South Korea , United States , Marcelo Matiello , Neuromyelitis Optica , Bruce Cree , Consortium Of Multiple Sclerosis Centers , Harvard Medical School , Horizon Therapeutics , California San Francisco Weill Institute , Medscape Medical , Multiple Sclerosis Centers , Drug Administration Approved , Expanded Disability Status Scale , Massachusetts General Hospital , Genomic Medicine , Edicine Genomic , Biologic Therapy , Monoclonal Antibody , Multiple Sclerosis Ms , Multiple Sclerosis , Attention Deficit Hyperactivity Disorder , Ttention Deficit Hyperactivity Disorder Adhd , Antineoplastic Drug , Nti Cancer Agents , Attention De ,